Freiburg Centre for Data Analysis and Modelling, Freiburg University, Freiburg, Germany.
Epidemiol Infect. 2013 Jan;141(1):158-64. doi: 10.1017/S0950268812000283. Epub 2012 Mar 7.
Chemotherapy and/or radiotherapy used as conditioning regimens before autologous or allogeneic haematopoietic cell transplantations (HCTs) cause neutropenia, which is the main reason for bloodstream infections. Autologous HCTs are considered to be superior to allogeneic HCTs in terms of infection outcome. A previous analysis suggested that patients with allogeneic HCTs are exposed to a reduced infection hazard and that an unfavourable infection outcome of allogeneic HCTs may be mediated through prolonged neutropenia. Therefore, we investigated whether allogeneic HCTs initially lead to fewer infections. We evaluated data from a prospective non-randomized multi-centre cohort study, with a total of 1616 patients. Of these, 703 patients received autologous and 913 patients received allogeneic HCTs from January 2000 to June 2004. The retrospective analysis used simultaneous confidence bands for the cumulative infection probability in the presence of competing risks. Patients with allogeneic HCTs experienced fewer infections during the early phase of neutropenia. As patients with autologous HCTs are not necessarily subject to antibiotic prophylaxis, a future study should investigate this policy. A limitation of the analysis is that it did not find the effect of crossing cumulative infection probabilities to be significant.
在自体或异体造血细胞移植(HCT)之前,使用化疗和/或放疗作为预处理方案会导致中性粒细胞减少症,这是血流感染的主要原因。与异体 HCT 相比,自体 HCT 在感染结果方面被认为更具优势。先前的分析表明,异体 HCT 患者的感染风险降低,而异体 HCT 感染结果不佳可能是通过中性粒细胞减少持续时间延长介导的。因此,我们研究了异体 HCT 是否最初会导致更少的感染。我们评估了一项前瞻性非随机多中心队列研究的数据,共纳入 1616 例患者。其中,703 例患者接受自体 HCT,913 例患者在 2000 年 1 月至 2004 年 6 月期间接受异体 HCT。回顾性分析采用同时置信区间来评估存在竞争风险时的累积感染概率。异体 HCT 患者在中性粒细胞减少的早期阶段感染较少。由于自体 HCT 患者不一定需要接受抗生素预防,因此未来的研究应该调查这一政策。该分析的局限性在于它没有发现交叉累积感染概率的效果具有统计学意义。